Document is current
Any future updates will be listed below
-
Authors
Hannaway, Naomi
Zarkali, Angeliki
Bhome, Rohan
Dobreva, Ivelina
Kalam, Sabrina
Thomas, George E. C.
Dymerska, Barbara
Belio, Irene Gorostiaga
Tucker, Katie
Heslegrave, Amanda
Zetterberg, Henrik
Weil, Rimona S.
-
Funding
Funding for this research was provided by:
Alzheimer’s Research UK (2018B-001)
Academy of Medical Sciences
Parkinson's UK
Wolfson Foundation
Eisai
Wellcome Trust (225263Z/22/Z)
Horizon 2020 Framework Programme
Alzheimer's Drug Discovery Foundation
Alzheimer's Association
UCLH Biomedical Research Centre
Rosetrees Trust
- License Information
-
More Information
Article History
Received: 25 November 2025
Accepted: 16 March 2026
First Online: 25 March 2026
Declarations
:
: All participants gave written informed consent and the study was approved by the Queen Square Research Ethics Committee (15.LO.0476), in accordance with the Declaration of Helsinki.
: Not applicable.
: RSW has received speaking and writing honoraria from GE Healthcare, Bial, Omnix Pharma, and Britannia; and consultancy fees from Therakind and Accenture. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp & Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD, is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, and is a shareholder of MicThera (outside submitted work). All other authors report no competing interests.
